Baricitinib (Olumiant®) for moderate to severe active rheumatoid arthritis

Assessment Status Rapid Review complete
Drug Baricitinib
Brand Olumiant®
Indication Treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Baricitinib may be used as monotherapy or in combination with methotrexate.
Assessment Process
Rapid review commissioned 14/06/2017
Rapid review completed 13/07/2017
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended at the Submitted Price

The HSE has approved reimbursement following confidential price negotiations November 2017